SC 13G: PORTAGE BIOTECH INC.

Ticker: ATON · Form: SC 13G · Filed: Feb 14, 2024 · CIK: 1095435

Portage Biotech INC. SC 13G Filing Summary
FieldDetail
CompanyPortage Biotech INC. (ATON)
Form TypeSC 13G
Filed DateFeb 14, 2024
Risk Levellow
Pages5
Reading Time6 min
Sentimentneutral

Sentiment: neutral

Topics: sc-13g

AI Summary

SC 13G filing by PORTAGE BIOTECH INC..

Risk Assessment

Risk Level: low

FAQ

What type of filing is this?

This is a SC 13G filing submitted by Portage Biotech INC. (ticker: ATON) to the SEC on Feb 14, 2024.

What is the risk level of this SC 13G filing?

This filing has been assessed as low risk.

How long is this filing?

Portage Biotech INC.'s SC 13G filing is 5 pages with approximately 1,499 words. Estimated reading time is 6 minutes.

Where can I view the full SC 13G filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,499 words · 6 min read · ~5 pages · Grade level 10.8 · Accepted 2024-02-14 15:50:16

Filing Documents

(a)Name of Issuer

Item 1. (a)Name of Issuer PORTAGE BIOTECH INC.

(b)Address of Issuer’s Principal

Item 1. (b)Address of Issuer’s Principal Executive Offices Clarence Thomas Building P.O. Box 4649, Road Town, Tortola British Virgin Islands, VG1110

(a)Names of Person Filing

Item 2. (a)Names of Person Filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"

(b) Address of Principal Business Office

Item 2. (b) Address of Principal Business Office: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United

(c) Citizenship

Item 2. (c) Citizenship: Armistice Capital, LLC - Delaware Steven Boyd - United States of America

(d)Title of Class of Securities

Item 2. (d)Title of Class of Securities Ordinary Shares, no par value (“Shares”)

(e) CUSIP No

Item 2. (e) CUSIP No.: G7185A128 CUSIP No. G7185A128 SCHEDULE 13G Page 5 of 8 Pages

If

Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) x An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) x A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: CUSIP No. G7185A128 SCHEDULE 13G Page 6 of 8 Pages Item 4.Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned as of December 31, 2023: Armistice Capital, LLC - 1,986,155 Steven Boyd - 1,986,155 (b) Percent of Class as of December 31, 2023: Armistice Capital, LLC - 9.99% Steven Boyd - 9.99% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote Armistice Capital, LLC - 0 Steven Boyd - 0 (ii) Shared power to vote or to direct the vote Armistice Capital, LLC - 1,986,155 Steven Boyd - 1,986,155 (iii) Sole power to dispose or

View Full Filing

View this SC 13G filing on SEC EDGAR

View on Read The Filing